Qilian International Holding Group Limited (NASDAQ:BGM) — Market Cap & Net Worth
Market Cap & Net Worth: Qilian International Holding Group Limited (BGM)
Qilian International Holding Group Limited (NASDAQ:BGM) has a market capitalization of $70.12 Million ($70.12 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20696 globally and #4616 in its home market, demonstrating a 14.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Qilian International Holding Group Limited's stock price $0.39 by its total outstanding shares 180623358 (180.62 Million). Review Qilian International Holding Group Limit balance sheet liabilities to assess the company's total debt and financial obligations.
Qilian International Holding Group Limited Market Cap History: 2021 to 2026
Qilian International Holding Group Limited's market capitalization history from 2021 to 2026. Data shows change from $2.32 Billion to $70.12 Million (-58.90% CAGR).
Index Memberships
Qilian International Holding Group Limited is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #591 of 976 |
Weight: Qilian International Holding Group Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Qilian International Holding Group Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Qilian International Holding Group Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
60.81x
Qilian International Holding Group Limited's market cap is 60.81 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.32 Billion | $57.10 Million | $3.15 Million | 40.67x | 736.62x |
| 2022 | $647.66 Million | $64.86 Million | $1.08 Million | 9.99x | 601.53x |
| 2023 | $696.30 Million | $46.47 Million | -$7.78 Million | 14.98x | N/A |
| 2024 | $1.53 Billion | $25.10 Million | -$1.44 Million | 60.81x | N/A |
Competitor Companies of BGM by Market Capitalization
Companies near Qilian International Holding Group Limited in the global market cap rankings as of June 19, 2026.
Key companies related to Qilian International Holding Group Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #631 globally with a market cap of $43.86 Billion USD ( CN¥299.75 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #634 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.27 |
| #631 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.86 Billion | CN¥46.99 |
| #634 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Qilian International Holding Group Limited Historical Marketcap From 2021 to 2026
Between 2021 and today, Qilian International Holding Group Limited's market cap moved from $2.32 Billion to $ 70.12 Million, with a yearly change of -58.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $70.12 Million | -89.48% |
| 2025 | $666.50 Million | -56.33% |
| 2024 | $1.53 Billion | +119.20% |
| 2023 | $696.30 Million | +7.51% |
| 2022 | $647.66 Million | -72.11% |
| 2021 | $2.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Qilian International Holding Group Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $70.12 Million USD |
| MoneyControl | $70.12 Million USD |
| MarketWatch | $70.12 Million USD |
| marketcap.company | $70.12 Million USD |
| Reuters | $70.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Qilian International Holding Group Limited
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufactu… Read more